Business Wire

LENOVO-GROUP

20.5.2020 01:17:11 CEST | Business Wire | Press release

Share
Lenovo Delivers Robust Revenue and All-Time Record Pre-Tax Income for FY19/20, Weathering Global Economic Challenges to Emerge in Position of Strength

Lenovo Group (HKSE: 992) (OTC Pink: LNVGY) today announced robust results for its full fiscal year and Q4, demonstrating the company’s position of strength amid unprecedented global transformation. Despite a fiscal year full of macro-economic and industry challenges, the company delivered full-year revenue exceeding US$50 billion (US$50.7 billion) for the second consecutive year. Profitability remained a strength, with historical high pre-tax income of US$1.02 billion, up almost 19% year-on-year. Full-year Net Income was US$665 million, up 12% year-on-year.

Basic earnings per share for the full year were 5.58 US cents or 43.61 HK cents, and for the fourth quarter the figure was 0.36 US cents or 2.80 HK cents. Lenovo’s Board of Directors declared a final dividend of 2.77 US cents or 21.50 HK cents per share for the fiscal year ended March 31, 2020.

“Amid one of the most significant periods of global change and transformation we have ever seen, Lenovo significantly transformed its business over the past year. From achieving record PTI of US$1.02 billion to reaching near record revenue of US$50.7 billion, I could not be prouder of our strong performance,” said Yang Yuanqing, Lenovo Chairman and CEO. “I am also unbelievably proud of how we continue to respond to the global pandemic, as both a business and a corporate citizen. While the world continues to face uncertain times, I’m confident Lenovo will leverage its operational excellence and global footprint to continue implementing our intelligent transformation strategy and fully grasp the opportunities our ‘new norm’ provides us.”

Global Economic Factors and Outlook

The last 12 months presented several industry-wide challenges, including geo-political uncertainties, component supply shortages, currency exchange impact, and in the fourth quarter the global COVID-19 pandemic. As relates to coronavirus, the business leveraged the power of 30+ inhouse and third-party manufacturing sites around the world to adjust capacity and rebalance production. This geographical balance and innate flexibility and resilience was at the core of the operational excellence shown throughout the year, ensuring the company continued to manufacture products and deliver orders to customers throughout Q4. Looking ahead, this foundational capability, together with ongoing innovation, will continue to drive business as the company seizes the long-term growth opportunities that the ‘new normal’ of working and studying from home is creating. This trend is not only leading to a growth in PC and smart devices, but also in the supporting data centers and infrastructure to power faster networks and digital consumption.

Fiscal Year Business Group Overview

Lenovo’s Intelligent Devices Group (IDG) continues to lead the company’s strong performance. The PC and Smart Devices group (PCSD), one of the two IDG business units, led the way with revenue for the year of almost US$40 billion, up 3.6% year-on-year. Profitability improved, with pre-tax income a record high of US$2.3 billion (more than 18% year-on-year) and an industry leading and record high PTI margin of 5.9%, up 0.7 points year-on-year. Leadership of the overall global PC market was extended, with share up more than 1 percentage point at 24.5% for the full year. This strong sustainable growth is driven by a consistent strategy to focus on and invest in high-growth segments, with Gaming, Workstations, Visuals, Thin and Light and Chromebooks each outgrowing the market by double-digits in volume.

IDG’s second business group, the Mobile Business Group (MBG), was on target for a breakthrough year until the fourth quarter impact of the required closure of the company’s primary smartphone factory in Wuhan due to COVID-19. Overall MBG revenue declined and pre-tax loss was US$43 million, greatly narrowed by US$96 million year-on-year. The business continued its focus on innovation, reentering the premium segment with the iconic foldable Motorola razr smartphone.

The Data Center Group (DCG) saw overall revenue decline 8.7% year-on-year due to softer Hyperscale demand and significant commodity price declines, but non-hyperscale revenue grew 5.3% year-on-year. This was driven by double-digit revenue growth in Software Defined Infrastructure (SDI), Storage, Software and Services. In particular storage revenue grew more than 50% year-on-year. In addition, non-hyperscale server volume grew by 14% and China revenue by 23% year-on-year. The company also extended its #1 leadership in High Performance Computing with 173 of the top 500 systems worldwide now running on Lenovo.

Transformation businesses demonstrated solid progress. Smart IoT revenue almost quadrupled (+296%) year-on-year driven by augmented and virtual reality, Smart Office and Internet of Things. Smart Infrastructure grew 37% year-on-year as Network Function Virtualization started to generate revenue. And Smart Vertical revenue more than doubled (+133%) thanks to strong growth in Data Intelligence Business Group, smart healthcare and smart education solutions. Software and Services had a breakthrough year with record revenue* of US$3.5 billion, up 43.2% year-on-year and becoming the catalyst for the Group’s overall transformation.

Q4 highlights:

  • Group revenue for the quarter was US$10.6 billion, down 9.7% year-on-year. Pre-tax income was US$77 million and Net income US$43 million.
  • PC and Smart Devices delivered a strong quarter. Revenue was down 4.4% year-on-year, but pre-tax Income improved by 15% (US$525 million v US$458 million) year-on-year, extending the company’s industry leading profitability by 1 whole point to a record high of 6.2%.
  • PC volume outgrew the market by four points, extending the company’s leadership and #1 global market position. PC revenue outgrew the market in all geographies around the world.
  • The Mobile Business Group was impacted by COVID-19 with the company’s primary global smartphone factory in Wuhan shut for much of the quarter. Despite this the business leveraged its global manufacturing footprint and produced 6 million phones during the quarter.
  • In Data Center, server volume continued double-digit growth (14%) year-on year. Hyperscale revenue remained a challenge due to a significant commodity price drop, but non-hyperscale business grew revenue almost 4% year-on-year, driven by the key growth and profit driver segments of Software Defined Infrastructure, Storage, Software and Services.

* Invoiced revenue

About Lenovo

Lenovo (HKSE: 992) (OTC Pink: LNVGY) is a US$50 billion Fortune Global 500 company, with 63,000 employees and operating in 180 markets around the world. Focused on a bold vision to deliver smarter technology for all, we are developing world-changing technologies that create a more inclusive, trustworthy and sustainable digital society. By designing, engineering and building the world’s most complete portfolio of smart devices and infrastructure, we are also leading an Intelligent Transformation – to create better experiences and opportunities for millions of customers around the world. To find out more, visit https://www.lenovo.com , follow us on LinkedIn , Facebook , Twitter , YouTube , Instagram , Weibo and read about the latest news via our StoryHub .

LENOVO GROUP

FINANCIAL SUMMARY

For the fiscal quarter and full year ended March 31, 2020

(in US$ millions, except per share data)

 

 

 

Q4
FY19/20

Q4
FY18/19

Y/Y CHG

 

FY19/20

FY18/19

Y/Y CHG

Revenue

 

10,579

11,710

(10)%

 

50,716

51,038

(1)%

Gross profit

 

1,861

1,895

(2)%

 

8,357

7,371

13%

Gross profit margin

 

17.6%

16.2%

1.4 pts

 

16.5%

14.4%

2.1 pts

Operating expenses

 

(1,695)

(1,622)

5%

 

(6,918)

(6,193)

12%

Expenses- to-revenue ratio

 

16.0%

13.9%

2.1 pts

 

13.6%

12.1%

1.5 pts

Operating profit

 

166

273

(39)%

 

1,439

1,178

22%

Other non-operating expenses - net

 

(89)

(93)

(5)%

 

(421)

(322)

31%

Pre-tax income

 

77

180

(57)%

 

1,018

856

19%

Taxation

 

(14)

(46)

(70)%

 

(213)

(199)

7%

Profit for the period/year

 

63

134

(53)%

 

805

657

22%

Non-controlling interests

 

(20)

(16)

35%

 

(140)

(60)

129%

Profit attributable to equity holders

 

43

118

(64)%

 

665

597

12%

Earnings per share (US cents)

 

 

 

 

 

 

 

 

Basic

0.36

1.00

(0.64)

5.58

5.01

0.57

Diluted

0.35

0.96

(0.61)

5.43

4.96

0.47

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye